Skip to main content

Year: 2025

Conavi Medical Reports Fiscal Year 2025 Results and Operational Highlights

Next-Generation Novasight Hybrid™ System Submitted to U.S. FDA for 510(k) Clearance U.S. and European Class 1A Guidelines Reinforce Growing Adoption of Image-Guided PCI Peer-Reviewed Publications Highlight Clinical Importance of Intravascular Imaging Leadership Team Expanded to Support U.S. Commercial Launch and Operational Scale-Up Company Advances Manufacturing, Conference Visibility, and Launch ReadinessTORONTO, Dec. 29, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal year ended September 30, 2025. “Fiscal 2025 was...

Continue reading

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Company to Continue Advancing Product Development and Regulatory Progress of Its Core Medical Pipeline Raanana, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that its Board of Directors has decided to explore realistic investment opportunities in revenue-generating real assets. The Company remains fully committed to its core medical device activities, continuing to advance product development, preclinical and clinical studies, and regulatory progress – including products such as PL-14 (allergy blocker), PL-16 (viral blocker), and the Trap & Target platform for intranasal drug delivery. In parallel, leveraging the Company’s strong cash position, the...

Continue reading

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission LOS ALTOS, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. “Our original third-party manufacturing vendor has made significant progress toward regaining FDA compliance, allowing us to resubmit the OLC NDA as planned,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With a cash...

Continue reading

Taboola to Participate in 28th Annual Needham Growth Conference

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in delivering performance at scale for advertisers, today announced that members of its management team will host one-on-one meetings and participate in a fireside chat at the Needham Growth Conference on Wednesday, January 14, 2026 at 1:30 p.m. ET. A live webcast and replay of the fireside chats will be available on Taboola’s investor relations website at www.taboola.com/about/investors. About TaboolaTaboola empowers businesses to grow through performance advertising technology that goes beyond search and social and delivers measurable outcomes at scale. Taboola works with thousands of businesses who advertise directly on Realize, Taboola’s powerful ad platform, reaching approximately 600M daily active users across some of the best publishers in...

Continue reading

Parsons Remains a Top U.S. Military-Friendly Employer

CHANTILLY, Va., Dec. 29, 2025 (GLOBE NEWSWIRE) — Today, Parsons Corporation (NYSE: PSN) is once again saluting military veterans, guard and reserve members, and their families, as the company celebrates additional recognition for its focus, investment, and commitment to employing military veterans. The company was recognized six times by various organizations for continued excellence and industry leadership in supporting the military community, including:2025 Department of Labor HIRE Vets Gold Medallion Award, given for proven metrics and achievement in veteran hiring, retention, resources, leadership, and compensation. 2025 Military Times Best for Vets Rankings, for overall strength of the MILVET program, ranked 2nd in the State of Virginia, 2nd in the Defense and Aerospace category, and 16th overall, the company’s highest rankings...

Continue reading

Auctions of mortgage covered bonds series 10F and 10G for the refinancing of FlexLån® and FlexLife®

To Nasdaq Copenhagen A/S   Executive ManagementBernstorffsgade 40DK-1577 København Vwww.rd.dk Telephone +45 7012 5300 29 December 2025Company Announcement number 106/2025 Auctions of mortgage covered bonds series 10F and 10G for the refinancing of FlexLån® and FlexLife® Realkredit Danmark will hold auctions on mortgage covered bonds for the refinancing of FlexLån® and FlexLife® with variable loan rate as of 1 April 2026. The auctions will be held from Tuesday 3 February to Friday 6 February 2026. The preliminary amounts and the distribution on specific ISIN’s are expected to change in the weeks to come. As a consequence, the specific auction dates for the individual ISIN’s will not be announced until the final amounts are known. The preliminary amount of bonds to be refinanced are set out in the appendix to this announcement. The...

Continue reading

Nuclear Diamond Batteries, Inc. (OTCID: WEDG) Announces Completion of Corporate Name Change Following FINRA Processing

Mesquite, NV , Dec. 29, 2025 (GLOBE NEWSWIRE) — Mesquite, NV December 29, 2025 GlobeNewsWire— Nuclear Diamond Batteries, Inc. (OTCID: WEDG) (“the Company”) today confirms that FINRA has completed processing of its corporate name change, and the Company’s new name is now reflected across OTC Markets and FINRA records as of December 29, 2025. Trading will continue under the ticker symbol WEDG. The Company’s new name aligns with its business direction following the acquisition of a controlling interest in Atomiq, Inc., which holds a nuclear diamond battery patent portfolio including one issued patent and additional applications pending divisional processing. This strategic position in Atomiq forms the foundation for the Company’s development roadmap and the branding transition to Nuclear Diamond Batteries, Inc. All future disclosures...

Continue reading

Datavault AI Inc. Announces Board Approval of Dividend of Dream Bowl Meme Coin II to All Eligible Record Equity Holders of Datavault AI

Innovative Dream Bowl Meme Coin II’s NFL Alumni Health addition will Commemorate the World’s First AI Powered Tokenized Bowl Game PHILADELPHIA, Dec. 29, 2025 (GLOBE NEWSWIRE) — Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ: DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today announced two major developments to enhance and elevate the profile of Dream Bowl XIV, scheduled for Jan. 11, 2026, at AT&T Stadium, of which the Company is a licensing partner and co-sponsor. First, Datavault AI, in collaboration with Dream Bowl XIV and NFL Alumni Health, proudly announces a strategic partnership supporting the launch of Dream Bowl Meme Coin II. This partnership underscores a shared commitment to advancing player health, wellness, and long-term care for former professional athletes,...

Continue reading

61/2025・Trifork Group: Weekly report on share buyback

Schindellegi, Switzerland – 29 December 2025 Trifork Group AGCompany announcement no. 61/2025 Weekly report on share buyback On 22 December 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052 (Safe Harbour regulation). The share buyback program runs from 23 December 2025 up to and including no later than 26 February 2026. For details, please see company announcement no. 58 of 22 December 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 219,735 treasury shares, corresponding to 1.1% of the share capital. Under the program, the following transactions...

Continue reading

PRESS RELEASE: Portfolio managers of three GAM-managed special situations funds publish open letter on Yutaka Giken tender offer

Albert Saporta, Co-CIO GAM AlternativesAlbert Saporta, Co-CIO GAM Alternatives, Group CEO GAM Holding AG, GAM Investment Management (Switzerland) AG, albert.saporta@gam.comRandel Freeman, Co-CIO GAM AlternativesRandel Freeman, Co-CIO GAM Alternatives, GAM InvestmentsLondon / Zurich, 29 December 2025 PRESS RELEASE Portfolio managers of three GAM-managed special situations funds publish open letter on Yutaka Giken tender offer Albert Saporta and Randel Freeman call for full transparency on the fairness analysis and a materially improved price to protect minority shareholders On the 22 December 2025 the portfolio managers of the GAM Japan Special Situations Fund, the GAM Special Situations Fund and the GAM Global Opportunities Fund published an open letter to the Chairman of Yutaka Giken Co., Ltd., regarding the proposed...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.